Croyle Recipient of Prestigious Hill Prize

A woman smiling.
February 5, 2024
Professor of Molecular Pharmaceutics and Drug Delivery and Glaxo Wellcome Professor Maria A. Croyle, Ph.D. is a recipient of the prestigious and highly competitive Hill Prize. The prizes, funded by Lyda Hill Philanthropies, accelerate high-risk, high-reward research ideas with significant potential for real-world impact.

Moczygemba Awarded PhRMA Foundation Grant for Sleep Tracking Research

A woman wearing a necklace and smiling.
December 7, 2023
Professor of Health Outcomes Dr. Leticia Moczygemba was awarded a planning grant to test and validate wearable sleep tracking sensors to improve health outcomes for people experiencing homelessness (PEH).

Croyle Wins Best Paper in 2022 Co-op Research Excellence Awards

A woman smiling.
November 4, 2022
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle, Ph.D. earned this year's Best Paper Award from the University Co-op Research Excellence Awards, presented by UT's Office of the Vice President for Research, Scholarship and Creative Endeavors and the University Co-operative Society.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

Improving Health Outcomes for People Experiencing Homelessness is Focus of New Study

Five people holding cell phones and wearing masks.
April 30, 2021
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Live Subject Testing Shows Promising Delivery Method for COVID-19 Antiviral Treatment

A microscopic image.
September 23, 2020
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.

New Delivery Method Could Make Niclosamide an Effective Antiviral to Treat COVID-19

Two men in suits smiling.
April 6, 2020
A team of researchers in the college, led by Robert O. (Bill) Williams III and Hugh D. Smyth, is investigating varying methods of drug delivery to repurpose existing drugs in order to treat and prevent serious COVID-19 virus symptoms in patients.

Croyle Lab Develops Innovative Vaccine Delivery Method

maria croyle vaccine 2020
March 4, 2020
Researchers in the lab of Dr. Maria Croyle have developed a peelable lightweight film that stabilizes biologics, is inexpensive, and withstands extreme temperature changes. The technology has already demonstrated proof of concept for model Ebola and H1N1 vaccines, and may prove an effective method of delivery for future treatments, such as for coronavirus that causes COVID-19.